News

Am 7. und 8. September findet die diesjährige Swiss Fintech Fair statt, die grösste Fintech-Messe der Schweiz. Im Zuge der besonderen COVID19-Situation haben die Veranstalter das Messe-Konzept um einen Digitaltag erweitert und setzen stark auf Internationalisierung.

Das Schweizer TrustTech-Start-up Skribble schliesst seine zweite Finanzierungsrunde ab. Der Anbieter für elektronische Signaturen hat Kapital im siebenstelligen Bereich mobilisiert. Angeführt wird die Runde vom Helvetia Venture Fund als Lead-Investor, auch die Mobiliar und die Mitarbeitenden haben sich beteiligt.

In einer Testanlage wird das ETH-Spin-off Synhelion ab 2023 synthetisches Gas aus Luft und Sonnenlicht herstellen. Die Flughafen Zürich AG wird dem Startup die gesamte verfügbare Jahresmenge des in der Testanlage produzierten nachhaltigen Treibstoffs abkaufen.

The Life sciences startups InterAX and Protemedix and ICT startups CodeCheck and Sparbatze have welcomed experienced industry leaders to support them on their growth journey. The new management members have previously worked in top management positions at renowned companies including Serono, Bank Cler and HelloFresh.

Not every Swiss start-up involved in Covid-19 research is developing a therapy. Companies also support researchers with digital tools, bioanalytical instruments and the production of proteins.

With $80M obtained from its series C round, Scandit the leading technology platform for mobile computer vision and augmented reality (AR) solutions for enterprises has sealed the largest Swiss VC round this year. G2VP, a Silicon Valley venture capital firm led the round with contributions from Atomico, GV, Kreos, NGP Capital, Salesforce Ventures and...

Die Crowdlending-Plattform Creditgate24 hat die KMU-Kredit-Plattform Advanon übernommen. Die Teams werden zusammengeführt, die Marke Advanon bleibt bestehen.

Zurich-based onCyt was launched in 2017 and has had paying customers for two and a half years. Based on their feedback and with the help of a Series A round, the existing product will now be adapted to fully exploit its potential. The goal is exponential growth.

Topadur, a developer of innovative drugs in stimulating local blood perfusion to enable wound healing, has submitted its first clinical trial application for its lead compound TOP-N53 for the treatment of chronic wounds such as diabetic foot ulcer. Pre-clinical tests showed encouraging results.

Winning international awards gives startups a confirmation that their innovation is outstanding on a global scale. Recently, five Swiss startups have received awards and honors from different competitions held across the world.